Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer

  1. Herzog, T.J.
  2. Pignata, S.
  3. Ghamande, S.A.
  4. Rubio, M.-J.
  5. Fujiwara, K.
  6. Vulsteke, C.
  7. Armstrong, D.K.
  8. Sehouli, J.
  9. Coleman, R.L.
  10. Gabra, H.
  11. Scambia, G.
  12. Monk, B.J.
  13. Arranz, J.A.
  14. Ushijima, K.
  15. Hanna, R.
  16. Zamagni, C.
  17. Wenham, R.M.
  18. González-Martín, A.
  19. Slomovitz, B.
  20. Jia, Y.
  21. Ramsay, L.
  22. Tewari, K.S.
  23. Weil, S.C.
  24. Vergote, I.B.
Revue:
Gynecologic Oncology

ISSN: 1095-6859 0090-8258

Année de publication: 2023

Volumen: 170

Pages: 300-308

Type: Article

DOI: 10.1016/J.YGYNO.2023.01.003 GOOGLE SCHOLAR

Objectifs de Développement Durable